Bactiguard's Decade-Best Quarter, Minus the Fine Print
License revenue up 40% and the adjusted EBITDA margin tripled to 34% — but the two questions that mattered most got soft answers
BACTI-B.ST · Earnings Call · 2026-10-22
The quarter that finally looked like a platform
Bactiguard is a SEK 565 million-market-cap medical device house whose entire economic engine is a coating — a noble-metal surface technology licensed to partners who put it on catheters and trauma implants. That model has historically produced interesting science and uninteresting financials. Q3 2026 is the quarter where the second part changed.
Total revenue came in at SEK 58.5 million against SEK 48 million a year earlier, with net sales up 24% at constant currency and the license business up 40% ex-FX. Adjusted EBITDA of SEK 20 million on a 34% margin was more than SEK 14 million better year on year — CFO Patrick Bach described it as "more than tripling our margin last year." Net profit swung to SEK 7 million, operating cash flow was SEK 14 million against a SEK 2 million outflow a year prior, and cash closed at SEK 55 million. Net debt, excluding leases, sits at SEK 64 million, roughly 1.2x rolling-twelve-month adjusted EBITDA.
That last number is the one that reframes the equity story. A licensing business with a fixed cost base and no debt problem converts incremental revenue at very high rates, and the company has now proven that arithmetic rather than asserted it.
We have lifted our adjusted EBITDA with more than SEK 125 million since our reported 2023 number, and our business model today allows us to accelerate and scale that further with increased demand in our license business.
BD: the stocking-effect elephant
The engine behind the quarter is BD, the Foley catheter partner Bactiguard has supplied since the early 1990s — more than 245 million coated catheters to date, with BD holding exclusive global rights outside China only since late 2023, and the agreement renewed earlier this year. BD contributed almost SEK 38 million in the quarter, up more than 30% ex-FX. Christine Lind called it the partnership's strongest growth in a decade, driven by both concentrate shipments and royalties on market sales, with new launches across the Nordics, Poland and parts of the Middle East now adding to established markets.
SEB's Mattias Vadsten went straight at the weak point: is this sell-in or sell-through? When a distributor launches in new countries, the first quarters can flatter the supplier with channel fill.
“We have confirmed with BD that we do not see, and they do not see, any significant stocking effects. We do not expect any changed downward momentum due to this in the future periods.” — Patrick Bach, CFO · 2026-10-22
That is a clean denial, and management reinforced it by declining to quantify anything granular — no split between existing and new markets, no count of new markets launched, no forward numbers. Investors are being asked to accept the growth as increased demand on faith. The rebuttal is structural: BD's rights only became global in late 2023, so the runway of unlaunched market launches is genuinely long, and Lind noted the countries launched so far are "far from the total number of places where they have market rights." If the sell-through claim holds for even two more quarters, the stocking worry dies on its own.
Zimmer: the answer the call didn't give
The more interesting evasiveness came on Zimmer Biomet. Under the amended agreement signed late 2025, Bactiguard gave up exclusivity on the trauma nail — now a non-exclusive arrangement — and shifted the economics toward royalties tied to in-market product sales. That is a deliberate trade of certainty for optionality, and it has an obvious accounting consequence: less guaranteed fixed fees, more variable royalty.
A written question asked exactly the right thing — what minimum component was removed, and what is the gross SEK run rate now versus the old structure. The answer restated the change without quantifying it:
“We today have a non-exclusive agreement for the trauma nail system which covers that. And we do have fixed fees as well as royalties coming from that agreement. Still within the total reported Zimmer numbers, we do have a majority of fixed fees in there, but we do see a growing amount coming from the in-market royalties.” — Patrick Bach, CFO · 2026-10-22
Zimmer contributed a bit over SEK 3 million. It is small, growing double digits on in-market sales, and still majority fixed-fee — so the transformation is real but early. The gap between the question and the answer matters: as royalties grow, the revenue line becomes higher quality but lumpier, and nobody on the call put a number on the crossing point. Management leans instead on Noble Metal Technology evidence — a joint publication with Zimmer comparing silver-containing surfaces, plus durability data and an independent University of Bari study on the ZNN Bactiguard nail — as the credibility layer under future orthopedics partner dialogue.
The tell in wound management
The segment that broke the pattern was wound management. Revenue of SEK 14 million fell just under 9% ex-FX, the direct cause being what the company calls order phasing — a phrase that lands at the top of this quarter's keyword set because it is doing a lot of work. Bach framed it as technical and partly regulatory-driven, and refused to size it:
“No, we did not quantify the order phasing as such. We obviously reported a record high Q2, and for the Q3, we see a softer quarter with close to 10% decline. The underlying demand that we see in our business is just as strong as of Q3 as it was in Q2.” — Patrick Bach, CFO · 2026-10-22
Strip out the quarter and the nine-month picture is roughly 14% organic growth led by Hydrocyn aqua, with double-digit full-year growth still guided. That is a coherent story, but it is also the second time this year the narrative has required investors to look through a single quarter. The difference between an order-phasing blip and demand erosion is precisely the thing that cannot be resolved from the outside until Q4 prints — and management has now pre-committed to "a strong quarter going forward."
What is actually new here
The unusual thing about this report is its isolation. The market's dominant themes this quarter are elsewhere entirely — rate-path keywords, tariff refunds, AI data center buildouts. Bactiguard shares a sector label with the medtech reporters in this cycle but almost none of their content. There is no macro wave lifting this name; the market traction is its own.
That cuts both ways. Nothing external can bail out a disappointing Q4, and nothing external explains the re-rating if the leverage holds. The bears' case is now narrow and specific: a tiny revenue base where a single partner represents roughly two-thirds of the quarter, a variable-royalty transition that reduces earnings visibility, a wound management segment that keeps needing an explanation, and a growth rate that management will not decompose. The bulls' case is simpler and, this quarter, better evidenced: flat OpEx against 21% revenue growth, a 34% adjusted margin, positive free cash flow, and net debt down to 1.2x.
Bactiguard also continues to fund the expensive parts of the model — MDR transition work across trauma implants and wound management, roughly SEK 6 million year-to-date in costs excluded from adjusted EBITDA, which the CFO flagged as a fair run rate into 2027. That is the honest asterisk on the headline margin: a chunk of the reported profitability is defined by what gets excluded. Still, the underlying direction is unambiguous. The 2030 targets were reiterated without numbers, partner dialogues in orthopedics were described as the strongest yet without a signature, and the application development pipeline was sketched in categories rather than deals.
Ten years of coating catheters has finally produced a quarter that looks like operating leverage rather than a research project. The next two quarters have to prove it wasn't channel fill and a calendar artifact.